Abstract
Background: During the last decades many successful efforts have been made in order to increase life expectancy in ovarian cancer (OC) patients. However, just a few studies have investigated the impact of OC on quality of life (QoL) and sexual function in OC cases during treatment. Objective: The aim of this study was to evaluate the QoL and sexual function of OC patients during chemotherapy (CT). Patients and Methods: Forty-nine subjects were enrolled and filled in the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-OV28, Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS) questionnaires. The results were evaluated globally and consequently stratified into several groups: single surgery versus multiple surgeries, age ≤48 years versus >48 years, and first-line CT versus multiple lines of CT. Results: Menopause-related symptoms, body image and attitude toward the disease were significantly worse during first-line CT (p = 0.018, p = 0.029 and p = 0.006, respectively). Sexual outcomes resulted in better scores in younger patients in all questionnaires (FSFI: p = 0.001; FSDS: p = 0.048; specific EORTC QLQ-OV28 items: p = 0.022). Scores concerning body image, attitude toward the disease and CT-associated symptoms resulted worse in patients after the first surgery (p = 0.017, p = 0.002 and p = 0.012, respectively). Conclusion: Our study confirms that OC has a detrimental impact on QoL and intimacy, particularly in younger patients, during the first course of CT and after the first cytoreductive surgery.
| Original language | English |
|---|---|
| Pages (from-to) | 205-210 |
| Number of pages | 6 |
| Journal | Oncology |
| Volume | 91 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy. / Domenici, Lavinia; Palaia, Innocenza; Giorgini, Margherita; Piscitelli, Valerio Piacentino; Tomao, Federica; Marchetti, Claudia; Di Donato, Violante; Perniola, Giorgia; Musella, Angela; Monti, Marco; Muzii, Ludovico; Panici, Pierluigi Benedetti.
In: Oncology, Vol. 91, No. 4, 01.10.2016, p. 205-210.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy
AU - Domenici, Lavinia
AU - Palaia, Innocenza
AU - Giorgini, Margherita
AU - Piscitelli, Valerio Piacentino
AU - Tomao, Federica
AU - Marchetti, Claudia
AU - Di Donato, Violante
AU - Perniola, Giorgia
AU - Musella, Angela
AU - Monti, Marco
AU - Muzii, Ludovico
AU - Panici, Pierluigi Benedetti
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background: During the last decades many successful efforts have been made in order to increase life expectancy in ovarian cancer (OC) patients. However, just a few studies have investigated the impact of OC on quality of life (QoL) and sexual function in OC cases during treatment. Objective: The aim of this study was to evaluate the QoL and sexual function of OC patients during chemotherapy (CT). Patients and Methods: Forty-nine subjects were enrolled and filled in the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-OV28, Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS) questionnaires. The results were evaluated globally and consequently stratified into several groups: single surgery versus multiple surgeries, age ≤48 years versus >48 years, and first-line CT versus multiple lines of CT. Results: Menopause-related symptoms, body image and attitude toward the disease were significantly worse during first-line CT (p = 0.018, p = 0.029 and p = 0.006, respectively). Sexual outcomes resulted in better scores in younger patients in all questionnaires (FSFI: p = 0.001; FSDS: p = 0.048; specific EORTC QLQ-OV28 items: p = 0.022). Scores concerning body image, attitude toward the disease and CT-associated symptoms resulted worse in patients after the first surgery (p = 0.017, p = 0.002 and p = 0.012, respectively). Conclusion: Our study confirms that OC has a detrimental impact on QoL and intimacy, particularly in younger patients, during the first course of CT and after the first cytoreductive surgery.
AB - Background: During the last decades many successful efforts have been made in order to increase life expectancy in ovarian cancer (OC) patients. However, just a few studies have investigated the impact of OC on quality of life (QoL) and sexual function in OC cases during treatment. Objective: The aim of this study was to evaluate the QoL and sexual function of OC patients during chemotherapy (CT). Patients and Methods: Forty-nine subjects were enrolled and filled in the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-OV28, Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS) questionnaires. The results were evaluated globally and consequently stratified into several groups: single surgery versus multiple surgeries, age ≤48 years versus >48 years, and first-line CT versus multiple lines of CT. Results: Menopause-related symptoms, body image and attitude toward the disease were significantly worse during first-line CT (p = 0.018, p = 0.029 and p = 0.006, respectively). Sexual outcomes resulted in better scores in younger patients in all questionnaires (FSFI: p = 0.001; FSDS: p = 0.048; specific EORTC QLQ-OV28 items: p = 0.022). Scores concerning body image, attitude toward the disease and CT-associated symptoms resulted worse in patients after the first surgery (p = 0.017, p = 0.002 and p = 0.012, respectively). Conclusion: Our study confirms that OC has a detrimental impact on QoL and intimacy, particularly in younger patients, during the first course of CT and after the first cytoreductive surgery.
UR - http://www.scopus.com/inward/record.url?scp=84991556227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991556227&partnerID=8YFLogxK
U2 - 10.1159/000447403
DO - 10.1159/000447403
M3 - Article
AN - SCOPUS:84991556227
VL - 91
SP - 205
EP - 210
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 4
ER -